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Abstract 
J. BRADLEY LAYTON: Acute Kidney Injury in Statin Initiators: Patterns of Initiation and 
Applications in Observational Drug Safety Research 
(Under the direction of M. Alan Brookhart) 
 Recent reports have suggested an increase in acute kidney injury (AKI) among users of 
statins, but non-experimental studies of statins face difficult, methodological challenges in estimating 
valid effect measure estimates. Conflictingly, some studies suggest a renal-protective effect of statins 
when used prior to heart surgery. To address these uncertainties, we assembled a large cohort of statin 
initiators and non-initiators using insurance claims from employer-based commercial and Medicare 
supplementary insurance plans. We investigated other medications initiated at the same time as the 
statin, and found that large numbers of statin users concurrently initiated other cardiovascular drugs, 
which may be a proxy of more severe disease risk, better medical care, better access to medical care, 
or increased health consciousness and behavior, all of which may be important confounding factors. 
We investigated the effect of statin initiation prior to heart surgery on post-surgical renal failure in a 
statin naïve cohort, considering concurrent medication initiation as covariates. We found a mild 
protective effect of statin initiation on post-surgical AKI: RR = 0.80, 95% CI 0.67, 0.96. This effect 
differed by age: ≥65 years, RR = 0.90 (95% CI: 0.71, 1.14); <65 years, RR = 0.69 (95% CI: 0.52, 
0.91), although AKI was much more common in the older age group (8.1 vs. 3.9%). In the general 
population, statins were not associated with an increased risk of AKI, nor were higher-intensity 
statins at greater risk than lower-intensity statins, or were individual statin formulations shown to be 
at higher risk than others, with the exception of higher-potency simvastatin, which demonstrated a 
slightly higher risk of AKI. Overall, there is no need for renal concern among typical statin initiators, 
and there may be small renal-protective effects, as well. 
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Chapter 1. Introduction and specific aims 
1. Introduction 
Statins are widely-used prescription medications for reducing serum lipoproteins, commonly 
used by older Americans (1) for both primary and secondary prevention of cardiovascular disease 
(CVD). They are prescribed over a spectrum of disease conditions including primary prevention of 
CVD in otherwise healthy individuals with cardiovascular risk factors, treatment of hyperlipidemia, 
or secondary treatment immediately post-major cardiovascular events (2-4). With such widespread 
use, it is critical to understand the risks associated with statin treatment (5). Although statins are 
generally accepted as quite safe, observational studies have suggested that statins may contribute to 
acute kidney injury (AKI), resulting in dialysis, loss of quality of life, or death, although these 
outcomes are likely rare (5, 6). Other studies have suggested that statins may be protective against 
renal injury in surgical settings. The disagreement between these associations may be due to and 
flawed study designs which fail to account for selection bias, confounding by disease severity, and the 
influence of the healthy user effect which may be present in epidemiologic studies of statin users. 
There is generally a lack of valid, population-based research on the topic, a reliable estimate of the 
overall risk and benefits of statin use on AKI is needed. 
2. Specific aims 
This study seeks to elucidate the relationship between statin initiation and AKI and describe 
the comparative safety of different statin formulations using contemporary pharmacoepidemiologic 
techniques and a large administrative claims database. A cohort of new statin users and comparison 
groups will be drawn from the Thomson Reuters MarketScan Research Databases which contain 
pharmacy and medical claims data for millions of employer-insured Americans.  
 2 
 
To better understand the relationship between statin use and renal outcomes and observe how 
considering peri-initiation factors can improve epidemiologic studies of statins, the following aims 
will be addressed with the following methods in this study: 
Aim 1: To characterize and describe new users of statin therapy in terms of other medications 
concurrently initiated with statins which may serve as important indicators of unmeasured clinical or 
behavioral characteristics. New users of statins will be identified along with their concurrently 
initiated medications.  
Aim 2: To estimate the effect of pre-surgical statin initiation on post-coronary artery bypass 
graft (CABG) AKI. A cohort of statin naïve patients prior to CABG will be identified, and the risk in 
those initiating a statin immediately prior to CABG will be compared to those not initiating a statin. 
Aim 3: To estimate the occurrence of AKI and other renal outcomes among new users of 
statins. A cohort of new statin users will be identified. The incidence of AKI will be estimated, and 
various comparison groups employed made to determine the relative hazards of renal injury in statin 
initiators and the comparative safety of statin formulations. 
  
 
 
 
Chapter 2. Background 
1. Statin Use 
Statins are widely used inhibitors of 2-hydroxl-3-methyl-3-glutaryl-CoA reductase, an 
enzyme involved in the production of cholesterol. Statins are frequently used for the reduction of 
levels of low-density lipoprotein cholesterol (7) and subsequently preventing cardiovascular events 
(8, 9). They have been demonstrated to be highly effective in preventing serious adverse outcomes 
(9), giving them an important role in modern medical practice of CVD management.  
Indication for statin use 
With such widespread use, multiple randomized, clinical trials, both placebo controlled (10) 
and head-to-head (11), have been conducted investigating statins’ efficacy for reducing serum 
lipoproteins and preventing cardiovascular events. Statins’ primary indications include: the reduction 
of acute cardiovascular and cerbrovascular events—myocardial infarction (MI), unstable angina, 
stroke, or revascularization—in patients without coronary heart disease (CHD) but with other 
cardiovascular risk factors (12-15); the reduction of CVD events in patients with coronary heart 
disease (12, 16); slowing the progression of atherosclerosis (13, 14, 16); and the reduction of serum 
lipid levels in patients with multiple forms of hypercholesterolemia (12-17). 
Recently, the indications for statin user have been expanded as rosuvastatin (marketed as 
Crestor®, AztraZeneca) has also recently been approved by the FDA for primary prevention of 
cardiovascular disease (CVD) in older Americans with normal blood lipids, but the presence of other 
CVD risk factors (18). Atorvastatin is also indicated for use as CVD preventives in diabetic patients 
with normal lipid levels (12).  The expansion of statins’ use into general CVD prevention has greatly 
increased the number of relatively healthy potential users of statins. 
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While multiple treatments for hyperlipidemia exist or are in development (19), statins remain 
the most commonly-used lipid lowering agent. The use of fibrates, another class of lipid-lowering 
medications, has increased in the United States over the past decade, in spite of a lack of evidence 
supporting their use in preference over statins (20) or even their ability to reduce incidence of 
coronary events (21).  
As hyperlipidemia and other cardiovascular diseases increase with the American obesity and 
diabetes epidemics, we can expect more widespread use of anti-lipid agents and the associated 
adverse events in the coming future (22).  
While statins are widely used for CVD, their role in renal disease and effect on renal function 
is less clear. Observational studies have suggested that statins may be very beneficial for kidney 
function; statins have demonstrated anti-inflammatory (2, 8) and renal/cardiovascular protective 
effects independent of their effect on lipids (3). Studies have suggested that statins may be protective 
to kidney function in the presence of diabetes (2), and a body of literature has emerged suggesting 
they may be prescribed prophylacticly to reduce or prevent renal injury (23-27) and other serious 
adverse events (23, 28-32) following cardiovascular surgery. However, recently epidemiologic 
analyses have suggested rare though serious renal adverse effects associated with statin use (33).  
Prevalence of statin use 
Statins are widely used throughout the United States, and are available in several popular 
formulations, including: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. 
Most formulations are also available in a variety of dosages, and occasionally as combination 
medications with other cardiovascular drugs. 
 Medication dispensing and expenditure estimates from 2010 reveal massive use of lipid 
regulators in the United States. Lipid regulators were the most widely-dispensed class of with just less 
than 4 billion prescriptions, and third in the amount of spending at approximately 18.8 billion dollars. 
Individual statin formulations were among the most widely-used individual products: simvastatin was 
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the most dispensed, and Lipitor® (atorvastatin calcium, Pfizer, Inc.) was the third most-dispensed. 
Lipitor® hard the largest expenditure of any single drug with 7.2 billion dollars spent in 2010 (34).  
NHANES data from 1999-2004 estimate that 58% of older Americans (men ≥50 years, women ≥60 
years) have an indication for statin use, and of this indicated group, approximately 42% were 
prescribed statins (1).  
Statin Safety 
Statins are generally considered safe and effective, yet even with a favorable risk/benefit 
profile, there are known, rare adverse events associated with statin use. Most well-known is statin—
induced muscle injury, including rhabdomyolysis—breakdown of skeletal muscle tissue resulting in 
muscle weakness, cramps, pain, or restricted mobility (5, 35). Indirect kidney injury can occur from 
rhabdomyolysis as excess muscle protein from rhabdomyolysis floods the blood stream, damaging 
nephrons in the kidney which may result in AKI. Statin packaging labels include warnings of muscle 
pain, rhabdomyolysis, elevated serum creatine kinase levels, myoglobinuria, and AKI (12-17). This 
effect on muscles has been observed in all statin classes, particularly those with higher dosages (36). 
Risk is also increased in interactions with other medications which may increase blood levels of 
statins, such as fibrates. The use of fibrates carries the risk of muscle and renal injury; increases in 
serum creatinine, an indicator of reduced renal function, have been regularly observed in fibrate 
monotherapy, and randomized trial data has demonstrated increased rhabdomyolysis in statin-
gemfibrozil combinations (37, 38). Most rhabdomyolysis symptoms appear within a few weeks of 
initiating a statin (6). Rhabdomyolysis is observed both in statin monotherapy and in combination 
with other drugs, including fibrates, anti-fungal medications, immunosuppressants, and others (5, 6). 
Whether or not statins also have an independent, toxic effect on the kidney is unknown.  
Non-lipid protective effects of statin 
Statins have been investigated heavily for evidence of protective effects and better outcomes 
in the surgical setting. Studies have demonstrated statins to be associated with a reduction in post-
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operative adverse events, including mortality, MI, stroke, coronary heart failure, arrhythmia, angina, 
and disease progression (32, 39). AKI remains a serious complication post-cardiovascular surgery, 
specifically resulting from the cardiopulmonary bypass occurring during and coronary artery bypass 
graft (CABG) surgery. It can result from many causes, including: the patient’s cardiovascular risk 
factors and disease severity which necessitated the surgery initially (40); embolism (41); 
hemodynamic effects of the surgery, including changes in renal blood flow and oxygenation (40); 
inflammation (40, 41); and ischemia-reperfusion injury (41). Heart surgery may result in rates of AKI 
as high as 30% with mortality rates among AKI sufferers of approximately 15 to 30%. Post-surgery 
renal impairment also increases risk of hospitalization and infection (40).  
It has been suggested by some epidemiologic studies that pre-operative use of statins may 
reduce the incidence of post-operative AKI or other serious renal events (24, 27, 29, 31), although 
this finding is not consistent, as additional studies have not demonstrated a protective effect (25, 41). 
This debated protective effect may be due, in part, to the healthy user effect (42).  
Statins have also been suggested to be protective against contrast-induced nephropathy (43), a 
common renal adverse event of patients undergoing radiological evaluation requiring a contrast agent. 
While contrast-induced nephropathy may be due to a different physiologic mechanism than 
rhabdomyolysis or post-CABG AKI, it underscores the scrutiny which statins are receiving regarding 
their renal-protective effects. Statins have been credited with many protective effects through 
observational studies, which may be due to biases inherent in the observational study of preventive 
medications (44). This study seeks to address this bias in investigating statin use and renal outcomes 
using large, administrative databases. 
2. Acute kidney injury 
AKI is a syndrome characterized by a sudden, marked decrease in kidney function (45). It is a 
broader term than the traditionally-used “acute kidney failure,” as AKI represents a spectrum of 
clinically-meaningful, sudden kidney dysfunction which may or may not require renal replacement 
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therapy (46). This potentially serious event is rare in healthy, community-dwelling individuals, but it 
is much more common in hospitalized patients, those undergoing procedures, those receiving 
medications, or those with comorbid conditions. An analysis of community-dwelling individuals in 
the Kaiser Permanente health system from 2002-2003 estimates the incidence of AKI not requiring 
dialysis as 522.4 (95% CI: 515.5-529.) / 100,000 person-years, and AKI requiring dialysis as 29.5 
(95% CI: 27.9-31.1) / 100,000 person-years. These estimated incidence rates appear to have increased 
over time, and tend to be higher in older age groups (47). Analysis of hospital discharge summaries of 
Medicare recipients from 1992 to 2001 have shown rates of AKI to be approximately 23.8 cases / 
1,000 discharges, again with rates increasing over time and higher rates among older age groups (48).  
Consequences of AKI can be severe. Sudden decreases in renal function have been associated 
with higher mortality rates: the more severe the renal impairment, the higher the death rate. Patients 
experiencing AKI have a high mortality rate and a high cost associated with emergency department 
visits and dialysis sessions, ranging from one week to six months. Studies have shown that AKI 
requiring dialysis results in an in-hospital mortality rate of ranging from 15% to greater that 50% (49, 
50). Patients with AKI who survive the initial hospitalization are at increased risk for mortality in the 
year following discharge (51), and may be at higher risk for the development and progression of 
chronic kidney disease (CKD) and end-stage renal disease (ESRD) (52). 
The etiology of AKI is complex, and may result from multiple difference pathways. The most 
common causes include: reduced blood flow leading to reduced renal perfusion (resulting from heart 
failure, renal artery stenosis, ischemia-reperfusion injury, arrthymias); volume depletion (resulting 
from blood loss/trauma, hypotension, dehydration); intrinsic renal factors (glomerulonephritis, 
autoimmunity, or other vascular causes); or urine obstruction (53). Drug-induced renal injury is a 
common concern of medication use, as most medication metabolites are processed through the 
kidneys. 
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While the etiology of AKI is complex, and multiple factors can contribute to its development, 
various prescription medications have been associated with increased incidence of AKI, both through 
direct effects on the kidney and indirectly through other mechanisms, such as rhabdomyolysis.  
Statins & AKI 
The information regarding the adverse effects of statins on the kidneys is mixed. It has been 
suggested that statin use may be beneficial towards overall kidney function (54), yet statins have not 
demonstrated the same cardiovascular protective effects on dialysis and renal transplant patients as in 
the general population (55). It has been suggested by one observational study that the risk of AKI 
may be increased in statin users (33). The association between statin use and rhabdomyolysis or other 
myopathies is generally clinically accepted, and rhabdomyolysis can lead to kidney and other organ 
failure. The molecular mechanism is not conclusively understood, although multiple hypotheses exist 
(6). Interestingly, rates of rhabdomyolysis seem to be increased in patients with impaired kidney 
function (55). However, in 2006 the Kidney Expert Panel of the National Lipid Association’s Safety 
Task Force issued a statement that there was not evidence suggesting a link between statin exposure 
and renal injury (56, 57). 
Whether there may also be an additional, independent toxicity of statins on kidney function 
remains unknown. Limited clinical evidence has suggested proteinuria as an occasional adverse event 
of use of certain statin formulations (58) and the previously mentioned non-experimental study 
suggests AKI across most statin formulations in both men and women (33). 
The risk of AKI in statin use is considered rare (5, 59), with existing estimates generally 
around 1 case per 10,000 person-years of use (varying depending on the type of statin or interactions 
with other coadministered drugs). Population-based estimates are not currently available, and 
estimates stratified by individual statin are generally unreliable, necessitating the investigation of AKI 
and statin use in a large, population setting with sufficient power to accurately estimate AKI risk.  
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While differences in rates of AKI have been observed and interactions with other medications 
suggested by case reports and small studies (60) , there are few reliable estimates of comparative 
safety among statin potencies. Reliable estimates of increased risk due to drug interactions are even 
more limited, due to underpowering of epidemiologic studies and highly-selected clinical trial 
samples. Statin use is widespread among older Americans (1), an age group likely to be taking 
numerous concurrent medications (61). 
3. Observational medication research 
This project will utilize non-experimental data sources—administrative insurance claims—to 
perform secondary data analysis. While there are many benefits of large, claims data, there are also 
many methodological challenges which must be addressed. 
Administrative claims-based pharmacoepidemiology 
Large insurance claims databases can be valuable data sources for studies of rare adverse 
drug events. Large numbers of observed individuals, often with sizeable amounts of observable 
follow-up time allow for easier identification of rare events. This study will employ two such large 
databases, the Thomson Reuters Commercial Claims and Encounters Research Database and the 
MarketScan Medicare Supplementary. 
Employer-based insurance coverage is the most common insurance state in the United States, 
with approximately 49% of the total population being covered by an employer-based health plan in 
2010 [68]. While the MarketScan databases represent a very large number of unique individuals, over 
65 million, from throughout the United States, there are limitations to the generalizability of the 
sample. Employed, insured individuals tend to be healthier than uninsured individuals (62), limiting 
somewhat the generalizability of findings from MarketScan-based studies to uninsured or 
unemployed demographics. Also, the employer-based health plans participating in MarketScan tend 
to be all large employers, without representation from small- or medium-sized employers (63). The 
employed population of MarketScan tends to be younger, not representing 65+ age groups. While the 
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MarketScan population is limited somewhat in population-representation, it is still a valuable tool for 
investigating disease-drug associations. 
All claims contained within the MarketScan databases resulting from pharmacy dispensing, 
outpatient services, or inpatient admissions have been paid and adjudicated, ensuring a high degree of 
accuracy and completeness. 
Prescription drug exposure information from claims 
Administrative claims databases obtain prescription medication data from pharmacy billing 
records submitted to insurance providers for reimbursement. Accurate prescription medication 
dispensing information from pharmacy claims is more reliable for assessing drug exposures than 
patient recall (64), and allows for more accurate identification of the medication formulation, dose, 
duration, etc. While dispensing claims are very accurate, as they are driven by pharmacy 
reimbursement, claims databases do not include direct patient measures of medication consumption—
such use must be assumed. Exact windows of exposure to the drug of interest can be very difficult to 
calculate from the dispending claims themselves. For this reason, many claims-based observational 
studies of medication effects generally employ an intention-to-treat, or first-exposure-carried-forward, 
design which assumes continuous exposure to the treatment determined during some initial window 
(typically the first or second prescription) until the event of interest or censoring. Intention-to-treat 
designs, while adding a small degree of exposure misclassification which may bias the effect 
measure, can also reduce the effect of informative censoring, which may be introduced if patients 
discontinue the use of their drug (and therefore, cease refilling the medication) due to the 
development of signs or symptoms of the outcome of interest. In the case of AKI which may be a 
condition with a sudden onset, this is a particular concern.  
While administrative claims databases can afford large numbers of participants for inclusion 
in studies of drug effects, they infrequently contain useful demographic or clinical information such 
as race/ethnicity, body mass index, smoking status. As the data generated in insurance claims is 
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driven by payment from insurers, claims for services and procedures will be submitted, but not 
necessarily the results of screening or diagnostic tests. Therefore, most claims databases will not have 
information on baseline kidney function, a strong predictor of AKI severity. 
Clinical information from claims 
In- and outpatient medical encounters by insured individuals result in bills generated by 
providers submitted to insurers. These bills contain documentation of procedures performed and the 
symptoms or diagnoses which justified the care received. These diagnoses form the source of disease 
information for most administrative claims-based epidemiologic studies. Diagnoses are reported as 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. 
These codes have been adopted under the Health Insurance Portability and Accountability Act 
(HIPAA) as the official coding scheme for healthcare settings (65). 
AKI has been studied in numerous database analyses, leading to questions regarding the 
validity of ICD-9-CM coding for AKI. Clinical definitions for AKI based on laboratory 
measurements exist (66), but the level of granularity present in precise clinical definitions may not be 
exhibited in diagnoses found in claims. Studies have estimated the validity of AKI definitions (see 
Table 2.1).  
Statin-induced renal injury may be more difficult to identify in claims data, as there is the 
intermediate muscle-injury in many cases, or possibly an independent effect. Therefore, distinct 
physiologic mechanisms of statin-induced muscle injury, rhabdomyolysis, and renal toxicity may not 
cleanly present itself in the dataset as one of the above-mentioned ICD-9-CM code definitions. Study 
of this multi-faceted syndrome in administrative claims databases will require greater investigation 
into the patterns of coding statin-induced muscle and kidney toxicities. 
The healthy user effect  
Initiation of and adherence to preventive medications and behaviors such as statins or simply 
adherence in general (67) may me a marker of a healthy lifestyle and other behavioral characteristics 
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which may place one at lower risk for mortality (68) and other adverse health events (69). These 
characteristics are ill-defined, and cannot be accurately measured or ascertained from administrative 
claims data. However, these differences have been demonstrated: adherent statin users were more 
likely to receive screening tests and vaccinations than non-adherent statin users (44, 69). The 
resulting bias—the “healthy user effect—has been documented, as studies have shown of 
physiologically implausible associations between statin adherence and reduced risk of outcomes such 
as burns, motor vehicle or workplace accidents, poisoning, skin infections, drug dependency, etc. 
(44). Studies of preventive medications, such as statins, must take great care to avoid these biases. 
Some of these biases can be addressed by choosing an active-drug comparison—physiologically 
distinct medication with a comparable behavioral profile (preventive daily medication with regular 
refills) (70)—rather than simply employing drug non-users. 
New user designs 
Observational studies of prescription medications typically employ a new user design which 
requires a baseline window of observed, unexposed time. This allows ascertainment of early events of 
interest (which may not be observed in studies using prevalent users) (71), allows for adjustment for 
disease risk factors prior to drug initiations (71) and reduces biases due to differential adherence or 
length of follow-up in comparison groups or depletion of susceptible individuals. 
These biases are particularly pronounced in older individuals where lack of preventive 
medication use may be more indicative of impaired health status (72). Utilizing a younger, employed, 
insured population for the study may reduce the influence of the healthy user effect. 
Statin new users 
Observational epidemiologic studies of medication use must address the confounding and 
bias introduced by non-randomized assignment of treatment. 
Statins have a wide spectrum of indications and a wide variety of dosages and potencies, 
making statin initiators a heterogeneous patient population. Statins may be used as primary 
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preventives in otherwise healthy individuals or given in combination with other cardiovascular drugs 
to high cardiovascular risk (73) or immediate post-MI patients (4). The heterogeneity of risk factors 
in statin initiators may introduce confounding when compared with generally healthy, non-medication 
using comparison groups. 
Statin comparative effectiveness and safety 
There are multiple different statin formulations of varying potencies, dosages, chemical 
structures, and metabolic pathways. While as a class, statins are generally considered quite safe, these 
structural and pharmacokinetic differences may result in differential risk of adverse muscle and 
kidney events (6). For example, cerivastatin was withdrawn from the market in 2001 due to safety 
concerns resulting from a high number of reported cases of fatal rhabdomyolysis to the FDA.  
Differing drug kinetics in statin formulations may also lead to differing muscle and kidney 
toxicities. Risk of toxicity seems to increase with level of statin exposure (74). Exposure level can be 
increased by higher dose, or differing pharmacokinetics (see Table 2.2). Statin formulations may be 
metabolized by different enzymes, leading to differential medication interactions which can further 
increase statin blood levels.   
These pharmacologic differences can create important within-class variations in drug action, 
including risk of adverse events, and should be considered in studies of the safety of statins. 
Considering statins only as a class of drugs may obscure important, individual drug effects. 
Individual statin formulations have exhibited unique safety profiles. Most prominent would 
be the withdrawal of cerivastatin from the market in 2001 due to an increased risk of fatal 
rhabdomyolysis. While all statins carry of risks of rhabdomyolysis, cerivastatin’s was far above that 
shown by the other drugs. Additionally, in clinical trials of Crestor® (rosuvastatin calcium, 
AstraZeneca), proteinuria has developed as an occasional adverse event (58). While this may be 
indicative of idiopathic kidney injury, industry-sponsored studies have not shown a reliable difference 
in rates of rhabdomyolysis or AKI in rosuvastatin users compared to other statins (75-78). Further 
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investigation into the comparative safety of statin preparations is warranted, as statins have multiple 
formulations of varying potencies, there is a documented history of AKI in some statin classes, and 
observational studies of statins tend to be plagued by well-described biases. 
  
 
4. Tables 
Table 2.1 Validation studies of acute kidney injury ICD-9-CM billing codes 
Study Outcome ICD-9-CM* Code Gold Standard Sensitivity Specificity PPV* NPV* 
Waikar 2006 (79) Acute renal 
failure 
584.5-584.9 100% change in serum 
creatinine 
35.4 97.7 47.9 96.1 
Waikar 2006 Acute renal 
failure 
584.5-584.9 Hou definition (80) 28.3 99.0 80.2 91.0 
Waikar 2006 Acute renal 
failure requiring 
dialysis 
584.5-584.9 + dialysis code Medical record review 
 
90.4 93.8 94.0 90.0 
Winterstein 2004 
(abstract) (81) 
Hospital-acquired 
acute renal failure 
584.xx Medical record review 15 83 87 -- 
*ICD-9-CM: International Classification of Diseases, 9th revision, Clinical modification; PPV: Positive predictive value; NPV: Negative predictive 
value 
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Table 2.2 Statin kinetics by formulation 
Statin Half-life Distribution Protein-
bound 
First pass liver 
extraction  
Absolute 
 bioavailability 
Peak plasma 
levels 
Metabolizing  
P450 enzyme 
Simvastatin (17) 3 hours  95% extensive <5%  P450 3A4, 3A5 
Rosuvastatin (13) 19 hours 134 liters 88%  20% 3-5 hours P450 2C9 
Atorvastatin (12) 14 hours 381 liters ≥98%  14% 1-2 hours P450 3A4 
Pravastatin (15) 77 hours  50% 0.66 ratio 17% 1-1.5 hours Minimal 
Lovastatin (14) 1.1–1.7 hours  >95% extensive <5% 2 hours P450 3A4 
Fluvastatin (16) <3 hours 0.35 L/kg 98%  24% <1 hour P4540 2C9 
16 
  
 
 
 
 
Chapter 3. Methods 
This retrospective, claims-based analysis will employ modern epidemiologic methods to 
address the aforementioned biases and issues using a very large, administrative claims database.  
1. Study Population 
This study will employ two large databases of insurance billing claims from the years 2000 to 
2010, the Thomson Reuters (Thomson Reuters (Healthcare) Inc.) MarketScan Commercial Claims 
and Encounters database (CCE) and Medicare Supplemental and Coordination of Benefit database. 
Both databases contain information about beneficiary plan enrollment, and paid, adjudicated billing 
claims from in- and outpatient procedures, diagnoses, and outpatient pharmacy-dispensed 
medications (63).   
MarketScan Commercial Claims and Encounters.  
The MarketScan CCE database contains de-identified insurance billing data from 
approximately 100 large, employer-based commercial insurance providers from throughout the 
United States. It provides longitudinal healthcare information and individual-level data on employed 
individuals, their spouses, and dependents. It is limited to those under age 65. It represents primarily 
those employed in large employers, under-representing those in small- or medium-sized employers 
(63).    
Approximately 49% of Americans received their health insurance coverage through an 
employer-sponsored health plan in 200 (63). While this database is very large (representing 
approximately 100 million unique lives throughout the included years), it is a non-representative 
sample of the general-US population, and is not representative of uninsured individuals, or those with 
Medicare or other governmental, or personally-purchased insurance plans. 
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MarketScan Medicare Supplementary and Coordination of Benefit 
The MarketScan Medicare database contains information on individuals with employer-based 
supplemental Medicare insurance. The database contains information on all healthcare claims for the 
individual including the Medicare-paid, employer-paid, and out-of pocket expenses. These databases 
include information on Medicare-eligible individuals aged 65 and older (63). 
Approximately 18% of Medicare beneficiaries received their coverage through an employer-
based Medicare supplemental plan, making this database a more highly-selected sample of the 
general population than the CCE.  
Included individuals 
We have data from the years 2000 – 2010 for both the MarketScan Commercial and Medicare 
databases. We will restrict the analysis to individuals 18 years and older at the index date of the study, 
as pediatric statin-users are likely very different from the adult statin-using population (82). 
2. Study design considerations 
New user designs 
All analyses will employ a new-user design. Non-experimental studies of prescription 
medications frequently employ the new user design (71) to reduce biases introduced by comparing 
long-term medication users to non-users. Selection bias by inability to observe early events (83) and 
unmeasured confounding by healthy lifestyle (69) are attenuated by restricting to new users where all 
person-time on the medication can be observed as follow-up. Many of the conflicting reports of statin 
safety and efficacy may be due to comparing prevalent users to non-users, so we have chosen to 
restrict all analyses to new initiators of the medications of interest. 
We will define new medication use as a pharmacy dispensing claims for a specific 
medication or medication class following 180 days of plan enrollment (the washout period) free of 
claims for the medication of interest (see Figure 3.1). If an individual has multiple eligible initiation 
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events, either due to plan un-enrollment and subsequent re-enrollment or medication discontinuation 
and the restarting after an eligible washout period, only the first index event will be considered. 
To ensure system utilization for pharmacy benefits, we will require all participants to have at 
least one medication claim for any medication other than the medication of interest during the 
washout period. By observing medication claims during this time, we are assured that the individuals 
are utilizing the insurance plan for which we have data for their prescription needs, and they are not 
filling their prescriptions from some other, non-observable source.  
Intent-to-treat analysis 
We will utilize an intent-to-treat, or first-exposure-carried-forward design, where the 
exposure assignment which was assigned on the index date is carried forward throughout follow-up, 
irrespective of subsequent prescription fills, switching, or discontinuation (84), a commonly-used 
technique in claims-based pharmacoepidemiology similar to those performed in randomized clinical 
trials.  Our administrative claims databases only contain information about medication dispensing, not 
actual consumption, making defining periods of medication use very difficult. Also, to avoid 
misclassification and informative censoring introduced by non-adherence, medication 
discontinuation, or medication switching due to the development of adverse events, the intent-to-treat 
analysis considers a patient exposed or unexposed continuously from the index date. This method 
introduces the potential for misclassification of exposure, but reduces the potential for informative 
censoring, thus giving more valid effect measure estimates.   
3. Innovation 
This study combines novel study designs with modern pharmacoepidemiologic methods to 
estimate the effect of statin on AKI in a variety of settings using a large administrative claims 
database. The resulting studies will be among the largest conducted on the subject including 
representation from the complete spectrum of adult ages. It will include a geographically diverse 
sample from across the United States and will employ methodologic improvements over prior studies, 
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including the use of a new user design and more comparable non-user comparison groups. A novel 
approach to characterizing disease risk using concurrent medication initiation will be employed, 
improving over previous, limited claims-based studies. Advanced analysis methods, including 
multiple propensity score techniques, will be employed.  
This study will substantially contribute to the fragmented literature regarding the role of 
statins in post-CABG surgery AKI and the small body of work on AKI in the general statin-using 
population. It will also introduce a new method of further characterizing baseline risk which is not 
explicitly hard-coded in claims data.  
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4. Figures  
 
Figure 3.1 New user design with intent-to-treat exposure analysis 
  
 
 
 
 
Chapter 4. Patterns of new statin use and concurrent medication initiation 
1. Introduction 
Non-experimental studies of prescription medications frequently employ the new user design 
(71) to reduce biases introduced by comparing long-term medication users to non-users. Selection 
bias by inability to observe early events (83) and unmeasured confounding by healthy lifestyle (69) 
are attenuated by restricting to new users where all person-time on the medication can be observed as 
follow-up. New-user studies of medications in administrative claims databases typically investigate 
claims (diagnoses, physician procedures, and dispensed medications) occurring during a 6-12 month 
baseline, or washout, period prior to drug initiation for evidence of conditions or procedures 
indicating a covariate of interest; this baseline period may or may not include the day of medication 
initiation, which may contain a substantial amount of information regarding relevant clinical factors 
which led to the patient’s initiation of the medication of interest. 
Medications are typically initiated in response to clinical encounters in which a patient’s 
health status is assessed, and necessary treatments are prescribed. While diagnosis codes are reported 
with billing claims to payers, they are motivated by reimbursement and are not always comprehensive 
indicators of a patient’s complete medical state. Many ICD-9-CM codes no not accurately convey 
relevant information about disease severity, results of laboratory measurements, or disease risk 
factors such as obesity, smoking, family history, etc.  
To fully control for potential confounding, researchers should ascertain relevant, available 
clinical information about a patient which may be related to the outcome yet is unaffected by the 
exposure (85). This can be challenging in the setting of administrative claims, which may give an in-
depth view of an individual’s billable healthcare expenses, yet often do not contain laboratory 
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measurements, health behaviors, and basic clinical or demographic variables. Proxies for unmeasured 
confounding factors must be used, in many cases. Medications initiated at the same time as the 
medication of interest may be an important proxy for relevant, unmeasured characteristics such as 
disease severity, quality of healthcare care, or health-seeking behavior, potentially adding valuable 
covariate information in statistical models of exposure-outcome associations. Failure to account for 
other medications initiated on the same day as the drug of interest may result in biased estimates of 
drug effects. 
Patterns of concurrent initiation of cardiovascular medications have not been described. This 
study describes the patterns of concurrent medication initiation among new statin users with related 
cardiovascular medications. 
2. Methods 
To investigate patterns of concurrent medication initiation, we identified a large cohort of 
new statin users using administrative billing claims. 
Study population 
Statin initiators were identified in Thomson Reuter’s MarketScan Commercial Claim and 
Encounters and Medicare Supplemental and Coordination of Benefits Databases (Thomson Reuters 
(Healthcare) Inc., 2011) databases for the years 2000 – 2010. Paid, adjudicated outpatient pharmacy 
dispensing claims were searched for evidence of statin initiation, defined as a claim for a pharmacy 
dispensing for any statin formulation following 6-statin free months of observed plan enrollment. One 
additional claim for any other medication was required during the washout period to ensure system 
utilization for pharmacy benefits. Statin use was categorized as either higher- or lower-potency statin 
according to product and dosage. 
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Concurrent medication initiation 
Initiation of other cardiovascular medication classes was assessed by identifying other 
medications dispensed on the same day as the index statin prescription. Medications dispensed after 
six months free of any other medication of the same class being dispensed were considered co-
initiated (see Figure 4.1). Considered drug classes include: antihypertensives, diuretics, anti-clotting 
agents, and non-statin anti-cholesterol drugs. Both statin-drug combinations (e.g. statin-ezetimibe, -
niacin, -calcium channel blockers) and separate prescriptions for other drug classes were considered 
to be co-initiated medications. Certain classes of unrelated medications were also included—proton 
pump inhibitors (PPIs), H2 blockers, anti-glaucoma medications, and non-steroidal anti-inflammatory 
drugs (NSAIDs)—to serve as markers of patterns of medication initiation resulting from a different 
disease process than that of the statin.  
Medication claims occurring during the washout period were considered prevalent 
medication use. 
Clinical information 
To assess cardiovascular risk, inpatient diagnosis codes were searched in the two weeks 
preceeding statin initiation for evidence of myocardial infarction (MI) or unstable angina.  Other 
baseline clinical characteristics were derived from in- and outpatient diagnosis codes and procedures. 
Statistical analysis 
Frequencies of cardiovascular medication class concurrent initiation were calculated, and 
distribution by potency, data source, cardiovascular risk, and other relevant factors were investigated. 
Frequency of cardiovascular drug initiation by year was explored, to determine if patterns of 
concurrent initiation have changed over time. 
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Sensitivity analyses 
Medications arising from the same clinical encounter may be filled on separate days due to 
issues of cost, supply, processing and billing practices, a physician’s sample being given for one 
medication but not the other, etc. Therefore concurrent may not necessarily imply the exact same day. 
To account for this variability, sensitivity analyses were performed expanding the allowable co-
initiation periods to 1, 3 and 7 days either before or after the index statin prescription. 
3. Results 
We identified 4,190,548 statin initiators during the time period of interest. Of the total statin 
initiators, 3,084,272 (73.6%) initiated a lower-potency statin, while 1,106,276 (26.4%) initiated a 
higher-potency statin. For clinical characteristics of the sample by statin potency, see Table 4.1. 
We observed concurrent initiation of at least one additional cardiovascular medication on the 
same day as the statin in 31.7% of new statin users. Of those who initiated at least one other CVD 
medication, the majority (60.6% of co-initiators, 19.2% of the total sample) initiated only one other 
medication, although individuals did initiate up to 9 additional medications on the same day as the 
statin (see Table 4.2). 
As the grace period was extended on either side of the statin index date, the proportion of 
patients initiating at least one other cardiovascular drug increased to 45.4% at 7 days. For some 
medications, increasing the grace period substantially increased the number of included initiators 
(angiotensin converting enzyme—ACE—inhibitors, beta blockers, thiazide diuretics), but for others, 
the increase was much less dramatic (see Figure 4.2).  
Striking differences in concurrent initiation patterns were seen in Medicare patients vs. 
commercially insured patients, and those with recent MI or unstable angina vs. the whole sample. 
Medicare patients tended to have much higher prevalent use of medications, with 80.9% initiating at 
least one other cardiovascular medication vs. 59.1% among the commercially-insured, but much more 
similar concurrent initiation (36.1% vs. 29.9%) (see Table 4.3). Conversely, among those patients 
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with recent coronary events (2.9% of the total sample), the rates of prevalent medication use were 
very similar to the overall sample, but the rates of concurrent initiation were much higher than the 
general sample (see Table 4.3). 
Higher-potency statin initiators tended to concurrently initiate slightly more cardiovascular 
medications than lower-potency statin users, with the notable exception of ezetimibe which is 
available in the common lower-potency statin-combination drug Vytorin® (ezetimibe/simvastatin, 
Merck & Co., Inc.). 
There was a slight trend toward increasing co-initiation of most drugs over time (see Figure 
4.3). Major changes were seen in the initiation of ezetimibe over time due to the introduction of a 
simvastatin-ezetimibe combination drug, Vytorin® in 2004. However, in 2008 the Ezetimibe and 
Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial 
demonstrated no benefit of statin-ezetimibe versus statin alone (86), quickly reducing its widespread 
use. When time trends were investigated among non-CVD medications, a decreasing trend was 
observed (see Figure 4.4). 
4. Conclusions and discussion 
Statins are frequently initiated with other cardiovascular medications, and the majority of 
concurrent initiation tends to occur on the same day as the statin.  
In patients recently experiencing MI or unstable angina, the overall concurrent medication 
initiation was higher than the overall sample (80.8% vs. 31.7%). Individual drugs classes which saw 
the most increase in use during this time period were ACE inhibitors (32.2%), beta blockers (54.7%), 
and anti-platelet agents (51.1%). These medications are all recommended for use post-MI (4) , and 
diagnosis or determination of high CVD risk may lead to initiation of these and other medications. 
This can be seen clearly in patients recently experiencing MI or unstable angina, where 80.8% of 
statin initiators concurrently initiated at least one other CVD medication. Among these patients, 
32.2% initiated an ACE inhibitor, 54.7% a beta blocker, and 51.1% an anti-platelet agent.  
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Older statin initiators seemed to have much higher prevalent use of other medications than 
younger individuals, yet comparable concurrent initiation—likely due to the already large use of other 
CVD drugs prior to statin initiation.  
Concurrent initiation has appeared to increase somewhat over the previous decade, perhaps in 
response to growing trends in diabetes, obesity, and other cardiovascular risk factors. Additionally, 
protocols and guidelines have consistently reinforced the control of lipids and hypertension in patients 
at high risk of cardiovascular disease and for secondary prevention (4, 87, 88). 
Even though unrelated to the indication for statins or other cardiovascular drugs, PPIs and 
NSAIDs were commonly concurrently initiated with a statin. Both of these medications are 
commonly used, however, in frail, commonly hospitalized, or chronically medicated patient 
populations. Therefore, co-initiation may result from the same clinical encounter, even if the 
indications for the two are unrelated. However, the addition of a non-related medication will likely 
not convey much information regarding the patient’s clinical state, and should not be included unless 
it can serve as a proxy for some important characteristic such as quality of care, etc.  
While having accurate and complete covariate information is critical for maximum control of 
confounding, it is unwise to simply include all available measures as covariates in statistical models. 
Inclusion of instrumental variables (89)—factors which influence exposure but are independent of 
outcome—or causal intermediates (90)—factors affected by the exposure which then affect the 
outcome—in statistical models may induce bias, rather than remove it (see Figure 4.5).  
Researchers have been rightfully warned against adjusting for covariates occurring after the 
assignment of the exposure for fear of adjusting for causal intermediates which may increase bias of 
the estimate (85), and therefore may systematically exclude all clinical information occurring at the 
same time or after the index date of medication exposure. While this may remove the potential for 
including causal intermediates, it may also remove potentially informative baseline variables. If 
researchers believe events occurring at the same time or immediately after the index prescription is 
unaffected by the exposure and reflective of a patient’s pre-treatment state, researchers should be 
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explicit in their assumptions regarding the inclusion of the characteristic. Additionally, it has been 
suggested that in many cases, medication initiation and adherence is a proxy for better access to 
healthcare, preventive service utilization, or healthy lifestyle (44, 69, 91, 92). In observational claims 
settings, it may be impossible to disentangle the effect of the medication from these other, 
unmeasured factors. However, considering other medications initiated at the same time as the drug of 
interest may give insights into the clinical and behavioral state of patients, allowing researchers to 
statistically control for these factors. This practice give researchers increased ability to control 
confounding present in claims-based studies of, resulting in less-biased estimates of medication safety 
and effectiveness. 
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5. Tables 
Table 4.1 Characteristics of the cohort by statin potency 
 Lower potency 
(N=3,084,272) 
Higher potency 
(N=1,106,276) 
 
DEMOGRAPHICS 
 
N 
 
% 
 
N 
 
% 
Male 1,435,198 46.5 574,192 51.9 
Database 
 Commercial Claims and Encounters 
 Medicare supplementary 
 
2,168,777 
915,495 
 
70.3 
29.7 
 
804,084 
302,192 
 
72.7 
27.3 
 
HEATLHCARE UTILIZATION 
 
Mean 
 
SD 
 
Mean 
 
SD 
Mean Age 58.7 12.8 58.1 12.2 
Lipid tests 0.83 1.01 0.82 1.05 
 
CVD MANAGEMENT 
 
N 
 
% 
 
N 
 
% 
Angiography performed 24,466 0.8 13,825 1.3 
Cardiac stress test performed 273,500 8.9 119,923 10.8 
Echocardiograph 360,239 11.7 151,349 13.7 
 
CVD & COMORBID CONDITIONS 
 
N 
 
% 
 
N 
 
% 
Diabetes 702,209 22.8 268,158 24.2 
Chronic kidney disease  66,113 2.1 28,155 2.6 
Hypertension 1,192,394 38.7 428,255 38.7 
Hyperlipidemia 1,413,924 45.8 526,194 47.6 
Other ischemic heart disease 375,041 12.2 193,213 17.5 
Atrial fibrillation 101,890 3.3 37,740 3.4 
 
ACUTE EVENTS IN PREVIOUS 6 MONTHS 
 
N 
 
% 
 
N 
 
% 
Myocardial infarction* 65,542 2.1 35,301 3.2 
Recent MI 47,471 1.5 27,140 2.5 
History of MI  17,195 0.6 9,327 0.8 
Unstable angina 27,170 0.9 12,952 1.2 
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Recent unstable angina  45,965 1.5 23,448 2.1 
Stroke 170,018 5.5 63,161 5.7 
Insertion of a coronary stent 60,821 2.0 37,421 3.4 
Angioplasty 9,229 0.3 4,801 0.4 
CABG 25,908 0.8 11,538 1.0 
Heart failure 96,102 3.1 39,438 3.6 
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Table 4.2 Number of medications concurrently initiated with a statin 
Number of medications N 
% of total sample 
(N=4,190,548) 
% of co-initiators 
(N=1,329,904) 
0 2,860,644 68.3 -- 
1 805,652 19.2 60.6 
2 328,369 7.8 24.7 
3 135,601 3.2 10.2 
4 44,352 1.1 3.3 
5 12,369 0.3 0.9 
6 2,971 0.1 0.2 
7 520 0.0 0.0 
8 66 0.0 0.0 
9 4 0.0 0.0 
 
  
 
Table 4.3 Medication use and initiation by primary insurance type 
 Prevalent Use Concurrent Initiation 
N=4,190,548 Commercial Claims 
(N=2,972,861) 
Medicare Supplement 
(n=1,217,687) 
Commercial Claims Medicare Supplement 
Drug N % N % N % N % 
Any CVD drug 1,755,901 59.1 985,582 80.9 889,996 29.9 439,908 36.1 
ACE inhibitor 727,362 24.5 391,664 32.2 262,472 8.8 121,732 10.0 
ARB 382,330 12.9 211,098 17.3 111,534 3.8 50,641 4.2 
Alpha blocker 93,441 3.1 103,723 8.5 33,720 1.1 30,390 2.5 
Beta blocker 592,342 19.9 457,700 37.6 199,531 6.7 137,283 11.3 
Calcium channel inhibitor 410,632 13.8 317,317 26.1 134,344 4.5 82,766 6.8 
Thiazide diuretics 693,812 23.3 350,463 28.8 176,210 5.9 75,393 6.2 
Loop diuretics 121,276 4.1 165,783 13.6 31,301 1.1 40,848 3.4 
Potassium-sparing diuretics 152,770 5.1 104,596 8.6 32,108 1.1 21,115 1.7 
Anti-platelet agents 112,763 3.8 129,416 10.6 83,828 2.8 66,832 5.5 
Fibrates 146,714 4.9 59,082 4.9 40,522 1.4 10,639 0.9 
Niacin 43,932 1.5 19,856 1.6 49,516 1.7 12,922 1.1 
Ezetimibe 72,037 2.4 47,968 3.9 213,180 7.2 72,763 6.0 
Anti-coagulants 66,563 2.2 105,250 8.6 15,671 0.5 23,215 1.9 
NSAIDs 573,770 19.3 236,183 19.4 69,001 2.3 31,078 2.6 
H2 inhibitors 77,651 2.6 59,325 4.9 14,763 0.5 11,332 0.9 
Proton-pump inhibitors 491,490 16.5 263,370 21.6 95,359 3.2 52,817 4.3 
Anti-glaucoma 41,033 1.4 83,857 6.9 3,611 0.1 7,077 0.6 
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Table 4.4 Same-day concurrent medication among patients with recent myocardial infarction or unstable angina 
N=122,611 Prevalent Use Concurrent Initiation 
Drug N % N % 
Any CVD drug 88,773 72.4 99,123 80.8 
ACE inhibitor 34,931 28.5 39,501 32.2 
ARB 16,860 13.8 3,707 3.0 
Alpha blocker 9.488 7.7 11,738 9.6 
Beta blocker 44,940 36.7 67,071 54.7 
Calcium channel inhibitor 26,368 21.5 8,120 6.6 
Thiazide diuretics 27,447 22.4 3,242 2.6 
Loop diuretics 14,631 11.9 11,415 9.3 
Potassium-sparing diuretics 7,788 6.4 2,725 2.2 
Anti-platelet agents 18,717 15.3 62,676 51.1 
Fibrates 4,726 3.9 1,385 1.1 
Niacin 1,333 1.1 2,012 1.6 
Ezetimibe 2,179 1.8 4,100 3.3 
Anti-coagulants 6,945 5.7 5,326 4.3 
NSAIDs 25,910 21.1 1,379 1.1 
H2 inhibitors 5,868 4.8 3,048 2.5 
Proton-pump inhibitors 27,621 22.5 11,437 9.3 
Anti-glaucoma drugs 4,478 3.7 223 0.2 
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6. Figures 
 
Figure 4.1 Schematic of the statin initiator cohort and concurrent initiation windows 
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Figure 4.2 Concurrent medication initiation over varying lengths of grace periods 
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Figure 4.3 Concurrent initiation of cardiovascular medications by year 
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Figure 4.4 Concurrent initiation of non-cardiovascular medications by year 
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Figure 4.5 Mechanisms by which concurrent initiation may occur. 1) a proxy for an unmeasured confounder (e.g. 
disease severity; 2) As a proxy for an instrumental variable without effect on the outcome ; 3) Given as a result of the 
initial medication 
  
 
 
 
 
Chapter 5. The effect of statin use on post-cardiac surgery acute kidney injury 
1. Introduction 
Acute kidney injury (AKI) is a serious complication of coronary bypass grafting (CABG) 
surgery. Post-surgical AKI can result in both short- and long-term consequences, including: 
prolonged hospital stays and cost (93); initiation of renal replacement therapy (94); development of 
chronic kidney disease (CKD) (95, 96) or end-stage renal disease (96, 97); or death (94, 96, 98, 99). 
There are currently no interventions known to attenuate the perioperative risk of AKI. 
Statins, potent inhibitors of HMG co-reductase, are well known to reduce the risk of 
cardiovascular disease mortality and morbidity (8). A growing body of literature now suggests that 
statins may also attenuate the risk of perioperative kidney injury. More specifically, epidemiologic 
studies have found an association between statin use prior to cardiac surgery and reduced risk of post-
surgical AKI (25-29, 99), dialysis (24), mortality (29, 31), and improved AKI recovery (23). These 
agents are postulated to have anti-inflammatory activity (100-102) and can stabilize endothelial 
function (103)—pleiotropic effects with potential benefits on kidney function (104). 
Yet, methologic issues raise questions about the plausibility of the observed renal-protective 
effects of statins (30, 41, 104). Non-experimental studies have employed widely varying definitions 
of pre-operative statin use, such as: having any prescribed statin use at the time of surgery (27-29, 31, 
41); administration the day of or the day before surgery (24, 26); or any prescribed use within the 90 
days prior to CABG (25). Many of these definitions fail to consider history or length of statin use, 
which may introduce bias due to the healthy user effect (44, 69) whereby immeasurable differences in 
behavioral characteristics, e.g. healthy lifestyle, between the treated and untreated may lead to 
exaggerated estimates of the benefits of preventive medications. This effect has been well-described 
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in outcome studies comparing prevalent statin user to non-users (44). These important methodologic 
concerns (105) limit the ability to distinguish whether the observed results are caused by a direct 
beneficial effect of statins, or rather, result from unmeasured differences in patient characteristics 
among long-term users of statins (42).  
To address these concerns, we assessed the effect of statin exposure on AKI risk using an 
epidemiologic design aimed at minimizing confounding bias. In patients undergoing planned CABG 
surgery who were not previously treated with a statin, we compare post-surgery AKI risk among 
patients initiating a statin immediately prior to surgery to patients not initiating statins. 
2. Methods 
Healthcare data 
Individuals undergoing CABG surgery between the years 2000 to 2010 were identified in the 
Thomson Reuters’ MarketScan® Commercial Claims and Encounters and Medicare Supplemental 
and Coordination of Benefits Databases (Thomson Reuters (Healthcare) Inc., 2011). These databases 
are a compilation of insurance billing data for employees, dependents and retirees from across the 
United States with primary or Medicare supplemental coverage through employer-based insurance 
plans. Adjudicated, paid inpatient, outpatient, and pharmacy claims, as well as enrollment 
information, are included in the databases.  
Study population 
All adult patients, aged  ≥18 years, with inpatient procedure claims for CABG, having two-
hundred days of continuous plan enrollment prior to hospital admission date for CABG were 
identified. If an individual had multiple eligible CABG surgeries, only the first was considered. The 
twenty days immediately prior to the date of hospital admission were considered the exposure 
window, during which statin initiation was assessed. The 180 days prior to the exposure window were 
considered the baseline or washout period, during which baseline characteristics and absence of statin 
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prescriptions were ascertained (see Figure 5.1). We required at least one pharmacy claim for any non-
statin medication during the baseline window to ensure pharmacy benefit utilization. 
Patients with evidence of AKI, unspecified renal failure, or end-stage renal disease before 
CABG were excluded. To remove individuals with emergency surgeries and restrict to planned 
CABG procedures, we excluded patients with inpatients claims for MI or unstable angina during the 
baseline period or CABG occurring after the fifth day of hospitalization. 
Treatments 
Statin initiation was defined as having a pharmacy dispensing claim for any statin during the 
exposure window without any statin claims during the preceding baseline period. A 20-day exposure 
window was chosen due to an observed increase in statin initiation immediately prior to CABG 
surgery (see Figure 5.2). Non-users had no observable statin use during the exposure or baseline 
windows and were required to have an outpatient physician’s office visit during the exposure window 
to ensure healthcare utilization.  
Covariates 
Baseline covariates included diagnoses, procedures, prevalent medication use, and pre-
operative initiation of other, non-statin medications. Racial/ethnic information was not available in 
the databases. Baseline diagnoses and procedures were assessed throughout the baseline and exposure 
windows. These covariates included: age; sex; year of surgery; number of coronary arteries bypassed; 
diagnoses of cardiovascular conditions; indicators of cardiovascular disease management (lipid tests, 
angiography, cardiac stress test, echocardiogram); acute cardiovascular events and procedures 
(unstable angina, myocardial infarction (MI), stroke, placement of coronary stent, angioplasty); 
evidence of renal conditions (chronic kidney disease, other kidney diseases, proteinuria, number of 
renal metabolism panels, etc.); number of emergency department visits; and number of 
hospitalizations. Any claims for cardiovascular medications during the baseline period were 
considered prevalent medication use. If the medications were initiated during the exposure window 
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without any use during the baseline period, the medications were considered newly-initiated and 
assessed separately in the analysis. 
Outcomes 
In-patient claims for the 15 days post-CABG were searched for evidence of AKI (ICD-9-CM 
codes 584.5 – 584.9). Sensitivity analyses were performed employing a broader definition of kidney 
failure (any of the following: acute renal failure, 584.5—584.9; end stage renal disease, 585.6; or 
unspecified renal failure, 586).  
Statistical analysis 
The association between statin initiation and AKI was estimated using multivariable Poisson 
regression to estimate adjusted risk ratios (RR) and 95% confidence intervals (CI) (106).  
We also performed a weighted regression analysis employing stabilized inverse probability of 
treatment weights (IPTW) (107). Multivariable logistic regression was used to estimate the predicted 
probability of initiating a statin, or propensity score (PS), for each individual in the sample. Predictors 
of statin initiation included the pre-specified covariates described above which were believed to 
capture relevant clinical characteristics, healthcare utilization, and risk factors for AKI. To exclude 
patients treated contrary to prediction due to the concern that their extreme weights may 
disproportionately influence the effect measure estimate (108), we identified individuals with a PS 
less than the first percentile of the treated, or greater than the ninety-ninth percentile of the untreated 
and excluded all patients with PSs below and above these cut-points. The PS was then used to 
calculate the IPTW in the remaining participants, and the weights were applied to a Poisson 
regression model of the effect of statin initiation on post-surgical AKI. 
Lastly, we performed one-to-one PS matching using a 5-to-1 greedy matching algorithm 
(109) where non-users were matched to statin initiators by propensity score to the 5th decimal place, if 
possible. We then estimated RR using regression models in the matched data. 
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Sensitivity analyses 
Sensitivity analyses were performed varying the length of the exposure window before 
CABG (10, 15, 25, and 30 days) to observe if the effect may be dependent on the length of time on 
statin prior to CABG. 
To estimate the extent to which medication initiation is simply a proxy for better pre-surgical 
care, the entire analysis was repeated considering beta-blocker initiation as a negative control 
exposure (110) rather than statin initiation as the primary exposure. Like statins, beta-blockers are 
preventive cardiovascular medications with a similar behavioral profile and user population as statins, 
but they are not thought to confer a protective effect against post-operative AKI. Therefore, if a 
protective effect was observed among the beta-blocker initiators, it can be assumed that our study 
design did not adequately address the healthy user effect and other sources of confounding bias. 
We performed additional analyses in pre-specified subgroups—gender, those without CKD, 
older vs. younger age—by stratifying by the characteristic of interest and performing the 
multivariable Poisson regression within the remaining subgroups. 
All statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC).  
This study was exempted from further review by the University of North Carolina 
Institutional Review Board. 
3. Results 
There were 149,696 patients with CABG surgeries with at least 200 days of observable 
enrollment prior to surgery. Excluding those with a history of statin use and others who did not meet 
inclusion criteria yielded 3,798 patients who initiated a statin within 20 days prior to CABG 
admission, and 20,898 who did not. Distributions of demographic and clinical variables by statin 
initiator status are shown in Table 5.1. The sample was predominantly male. Statin initiators were 
predominantly commercially-insured, whereas statin non-initiators were as likely to be covered by 
Medicare or commercial insurance. Variables were generally well-balanced across treatment groups, 
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with the notable exceptions that statin initiators were more likely to have received echocardiographs 
and cardiac stress tests, have diagnoses of hyperlipidemia and ischemic heart disease, and were more 
likely to initiate other cardiovascular medications. While some of these are usually associated with 
increased risk for CVD outcomes, in claims data all of these factors may also be seen as markers of 
better disease management, preventive behavior, healthcare utilization, or pre-operative care. The 
propensity score distribution by statin treatment group was plotted, and we observed considerable 
overlap between the treatment groups (see Figure 5.3). 
Post-CABG AKI occurred in 1,301 (6.2%) of the non-initiators and 140 (3.7%) of the 
initiators. Crude regression models yielded a highly-protective effect measure estimate, but when 
adjusted for clinical characteristics and other medication, the estimate attenuated to RR=0.81 (95% 
CI: 0.67, 0.97) (see Table 5.2).  
We calculated IPTW weights from the propensity scores. The weights did not differ 
meaningfully between higher- and lower-potency statin formulations. When the regression analysis 
was performed with IPTW weighted models, the effect was very different, with RR=1.23 (95% CI: 
0.86, 1.75). However, fearing the influence of large weights among individuals with residual 
unmeasured confounding, we trimmed PS less the 0.5th percentile of treated and greater than the 
99.5th percentile of the untreated, yielding an effect estimate of RR=0.82 (95% CI: 0.65, 1.03) (see 
Table 5.2). Further trimming of the PS distribution did not yield meaningfully different estimates. PS 
matching also yielded similar estimates, with RR=0.75 (95% CI: 0.59, 0.93).  
We observed no meaningful differences in effect estimates between male and female patients, 
nor when restricted to only patients without chronic kidney disease. When investigating the effect 
measure estimates by age, the protective effect was more pronounced in younger individuals < 65 
years RR=0.69, 95% CI: 0.52, 0.91) than older individuals (RR=0.90, 95% CI: 0.71, 1.14). AKI was 
much more common in the older age group (8.1%) than the younger age group (3.9%). 
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When the exposure window before CABG was varied, the effect measure estimate tended to 
remain constant (see Figure 5.4). Additionally, when a wider definition of kidney failure was 
employed, the results remained essentially unchanged (see Table 5.2).  
When the analysis was repeated considering beta-blocker initiation in the place of statin 
initiation, we observed no protective effect of beta blockers initiation against post-CABG AKI, with 
multivariable adjusted models yielding RR=0.95 (95% CI: 0.83, 1.09) and trimmed IPTW models 
yielding RR=1.04 (95% CI: 0.89, 1.21).  
4. Discussion 
In this cohort study of nearly 25,000 participants, we found that initiation of a statin just prior 
to CABG surgery was associated with a slightly decreased risk of post-CABG AKI compared to no 
statin initiation. While the crude relative risk suggested a strong protective effect of statins, after 
multivariable adjustment, the effect was attenuated toward the null, yielding a smiliar estimate to the 
PS-matched analysis. Large weights among those in the tails of the propensity score distribution may 
have unreasonably contributed to the IPTW analysis, so the weights were trimmed from the bottom 
percentiles of the treated and the top percentiles of the untreated. These trimmed propensity score 
weighted analyses yielded a similar effect estimate as the multivariable model, but with greater 
uncertainty surrounding it. The results were robust in various sensitivity analyses. 
A stronger effect measure estimate was observed among those under age 65 than in the older 
age group. A similar trend of decreasing efficacy in older age groups for the prevention of post-
surgical renal replacement therapy has been shown in previous literature (24). While the protective 
effect was more pronounced, younger individuals experienced many fewer post-CABG AKI events 
overall, suggesting that the absolute benefit of statin treatment may not be as dramatic as the relative 
RR suggests (111). 
We adopted a design explicitly aimed at minimizing the healthy user effect, a potentially 
important bias in non-experimental studies of statins, and other sources of confounding bias. First, we 
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restricted our study to patients who initiated a statin immediately prior to surgery and compared these 
with patients not initiating a statin. By excluding long-term statin users from the exposed cohort, we 
sought to exclude patients who were likely to be healthier and more engaged in other prevention-
oriented behaviors. Second, we excluded patients who were receiving CABG emergently after a 
hospitalization for MI or unstable angina, or late into a complex hospitalization. By doing this, we 
sought to create a more homogeneous group of patients. We speculated that statin initiation in these 
patients would be more dependent on physician preference or protocol than clinical factors, such as 
complexity of surgery, or patient behavioral characteristics.  
Secondly, we attempted to remove remaining differences between the groups by adjusting for 
a wide array of clinical and prevalent characteristics. Prevalent medication use and concurrent 
medication initiation were considered as separate covariates in this analysis. Prevalent medication use 
was very similar between the two treatment groups, but statin initiators tended to initiate other 
medications at a much higher rate during the exposure window. Considering other pre-operative 
medication exposure allows us to more accurately assess pre-operative care and adjust for differences 
which may exist between the statin and non-statin groups. 
Lastly, we also examined the effect of beta-blocker initiation on post-CABG AKI as a 
negative control. Beta blockers are prescribed to improve post-CABG outcomes, but are not thought 
to be linked with reduced AKI risk, so we would not expect an effect of beta-blocker initiation on 
AKI, and any observed protective effect among beta blocker initiators would suggest residual 
confounding rather than a physiologic effect of the drug. Beta blocker initiation did not lead to a 
reduction in AKI risk, suggesting that the observed effect estimate among the statin users may be a 
real effect, not simply unmeasured behavioral or clinical factors for which any medication initiation 
serves as a proxy (91). 
Other published estimates of the effect of perioperative statin use on post-operative AKI have 
ranged from strongly protective (27), to null (41, 112). Our estimate—approximately a 20% reduction 
in risk with a wide confidence interval—is comparable to other studies of the subject (25, 30, 104). 
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Statins have been attributed with anti-inflammatory and renal- or cardio-protective effects 
independent of their lipid-lowering function (3). Consequently they have been investigated widely in 
non-experimental research for preventive effects. However, studies of statins and other preventive 
medications must take care to avoid study design pitfalls which can inflate protective effect measure 
estimates. 
The findings of the study should be interpreted in the context of the following limitations. 
First, despite our attempts to make the treatment groups comparable, we observed some difference 
between groups which may indicate better health status, and thus better outcomes among statin users. 
Although, we controlled for these observed factors in our analysis, some of the variables, such as 
CKD have been shown to have poor validity (113), which would allow for some residual confounding 
by baseline renal impairment to remain. Similarly, the validity of AKI billing codes has been 
investigated, and the sensitivity has been shown to be very poor. However, the specificity of AKI 
coding has been shown to be very high (113). Under the assumption of nondifferential 
misclassification of the outcome between the statin treatment groups, the RR should be unbiased 
under these conditions (114, 115). 
Third, these particular results may not be fully generalizable to the entire CABG population. 
Attempting to replicate a design similar to that of a clinical trial where a physician would have the 
opportunity to prescribe a statin to a previously statin-naïve patient prior to a known upcoming 
surgery, this analysis was restricted to only planned, non-emergency CABG surgeries among those 
patients without a history of statin use; the vast majority of patients undergoing CABG had evidence 
of prevalent statin use, and thus did not meet our inclusion criteria for this analysis. Yet, the findings 
were consistent through sensitivity analyses varying the time during which initiation was considered 
and a broader definition of kidney failure.  
Statins are a mainstay of cardiovascular prevention, and are routinely prescribed to those at 
highest risk for cardiovascular events. However, as observational research of statins continues to 
suggest additional protective and beneficial effects, careful consideration must be given to the designs 
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of non-experimental studies to ensure that they do not fall prey to biases common to studies of 
preventive medications. After considering the timing of statin initiation, observing the entire length of 
statin treatment, measuring important markers of pre-clinical care, and matching non-users to users on 
healthcare utilization, our study supports the hypothesis that prescribing a statin prior to CABG may 
modestly attenuate the incidence of post-CABG AKI among those not already receiving statin 
therapy. 
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5. Tables 
Table 5.1 Baseline demographics and clinical characteristics by statin initiation status 
 Statin Non-initiator 
(n=20,895) 
Statin initiator 
(n=3,798) 
DEMOGRAPHICS     
Male, % 15,378 73.6 2,993 78.8 
Mean age, standard deviation (SD) 65.2 10.9 62.5 10.1 
MarketScan Database 
 Commercial Claims and Encounters Database, % 
 Medicare Supplementary Database, % 
 
 
10,759 
10,136 
 
51.5 
48.5 
 
2,402 
1,396 
 
63.2 
36.8 
HEATLHCARE UTILIZATION Mean SD Mean SD 
CABG on day of hospitalization 1.36 1.47 0.79 1.24 
Lipid tests* 0.63 1.06 0.83 1.11 
Creatinine measurements* 0.03 0.32 0.02 0.24 
Hospitalizations* 0.20 0.54 0.19 0.55 
Emergency department visits* 
 
0.14 0.49 0.19 0.55 
CARDIOVASCULAR DISEASE MANAGEMENT N % N % 
Angiography performed 286 1.4 108 2.8 
Cardiac stress test performed 10,702 51.2 2,550 67.1 
Echocardiograph 
 
9,332 44.7 1,940 51.1 
CVD & COMORBID CONDITIONS N % N % 
Number of vessels bypassed during CABG 
 1-2 
 3-5 
 6+ 
 
7,400 
11,681 
1,814 
 
35.4 
55.9 
8.7 
 
1,166 
2,198 
434 
 
30.7 
57.9 
11.4 
Diabetes 5,860 28.0 984 25.9 
Chronic kidney disease  865 4.1 86 2.3 
Other kidney disease 152 0.7 18 0.5 
Proteinuria 87 0.4 13 0.3 
Hypertension 9,962 47.7 1,887 49.7 
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Hyperlipidemia 5,910 28.3 1,487 39.2 
Other ischemic heart disease 13,265 63.5 3,161 83.2 
Atrial fibrillation 
 
1,498 7.2 167 4.4 
ACUTE EVENTS IN PREVIOUS 6 MONTHS N % N % 
Myocardial infarction (MI)†  777 3.7 138 3.6 
History of MI  415 2.0 92 2.4 
Unstable angina† 2,544 12.2 571 15.0 
Stroke 3,378 16.2 713 18.8 
Insertion of a coronary stent 311 1.5 64 1.7 
Angioplasty 
 
205 1.0 53 1.4 
PREVALENT MEDICATION USE DURING 
BASELINE 
N % N % 
Angiotensin converting enzyme (ACE) inhibitors 6,270 30.0 1,113 29.3 
Angiotensin receptor blockers (ARBs) 3,242 15.5 534 14.1 
Beta blockers 7,028 33.6 1,183 31.2 
Calcium channel blockers 4,797 23.0 742 19.5 
Anti-platelet agents 2,086 10.0 281 7.4 
Alpha blockers 1,856 8.9 248 6.5 
Thiazide diuretics 4,822 23.1 841 22.1 
Potassium-sparing diuretics 1,284 6.1 152 4.0 
Loop diuretics 2,360 11.3 261 6.9 
Niacin 358 1.7 52 1.4 
Fibrates 1,391 6.7 191 5.0 
Ezetimibe 911 4.4 100 2.6 
Anti-coagulants 1,332 6.4 136 3.6 
Non-steroidal anti-inflammatory agents 
 
4,012 19.2 696 18.3 
MEDICATIONS INITIATED DURING EXPOSURE 
WINDOW 
N % N % 
ACE inhibitors 1,892 9.1 709 18.7 
ARBs 760 3.6 213 5.6 
Beta blockers 3,663 17.5 1,702 44.8 
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Calcium channel blockers 1,328 6.4 367 9.7 
Anti-platelet agents 778 3.7 310 8.2 
Alpha blockers 678 3.2 276 7.3 
Thiazides 1,181 5.7 271 7.1 
Potassium-sparing diuretics 336 1.6 57 1.5 
Loop diuretics 785 3.8 142 3.7 
Niacin 96 0.5 59 1.6 
Fibrates 358 1.7 76 2.0 
Ezetimibe 203 1.0 226 6.0 
Anti-coagulants 371 1.8 58 1.5 
NSAIDs 766 3.7 107 2.8 
*Occurring within the 200 days prior to admission for CABG surgery 
†Not including events which occurred in the 20 days prior to hospital admission for CABG as those 
patients were excluded 
  
  
 
Table 5.2 The effect of statin initiation on statin on post-CABG acute kidney injury and any renal failure 
 
   Acute kidney injury Any renal failure 
Model Treatment Group N Events (%) Risk ratio 95% CI* Events (%) Risk ratio 95% CI 
-- Non-initiator 20,895 1,301 (6.2) -- -- 1,540 (7.4) -- -- 
Crude Statin initiator 3,798 140 (3.7) 0.59 0.50, 0.70 154 (4.1) 0.56 0.47, 0.66 
Multivariable adjusted    0.81 0.67, 0.97  0.77 0.65, 0.92 
         
IPTW*, untrimmed Non-initiator 20,895 1,301 (6.2) -- -- 1,540 (7.4) -- -- 
 Statin initiator 3,798 140 (3.7) 1.23 0.86, 1.75 154 (4.1) 1.13 0.81, 1.59 
         
IPTW, ≤0.5th,  ≥99.5th 
percentiles trimmed 
Non-initiator 20,208 1,219 (6.0) -- -- 1,378 (6.8) -- -- 
Statin initiator 3,499 128 (3.7) 0.86 0.68, 1.09 138 (3.9) 0.82 0.66, 1.03 
         
IPTW, ≤1th,  ≥99th 
percentiles trimmed 
Non-initiator 19,751 1,169 (5.9) -- -- 1,317 (6.7) -- -- 
Statin initiator 3,345 124 (3.7) 0.85 0.67, 1.06 134 (4.0) 0.82 0.65, 1.02 
         
Propensity score 
matched 
Non-initiator 3,547 177 -- -- 193 -- -- 
Statin initiator 3,547 132 0.75 0.59, 0.93 142 0.74 0.59, 0.91 
*95% CI: 95% Confidence interval; IPTW: Inverse probability of treatment weighting 
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6. Figures 
 
 
Figure 5.1 Schematics of new statin users and non-users prior to coronary artery bypass graft surgery 
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Figure 5.2 Statin initiation prior to coronary artery bypass graft surgery in commercially-insured patients 
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Figure 5.3 Distribution of predicted probability of pre-CABG statin treatment by treatment status 
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Figure 5.4 Effect measure estimates across varying exposure windows 
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Chapter 6. Acute kidney injury in statin initiators 
1. Introduction 
Use of statins has become widespread in the United States over the past decade (1, 34). They 
have become a mainstay of lipid management, and an integral part of both primary and secondary (4) 
cardiovascular disease (CVD) prevention. They are widely used by older individuals at risk of CVD 
(1) and are highly effective in preventing serious adverse outcomes (9). Additionally, it has been 
suggested that statins have anti-inflammatory (101) and other protective effects (2, 103, 116) beyond 
their primary lipid-lowering function. They have also begun to be used as preventives in patients at 
much lower CVD risk (117).  
As these medications are used in younger and healthier individuals, safety and even rare 
adverse events have justifiably become serious considerations to ensure that potential negative effects 
do not outweigh the well-established cardiovascular benefits of statin use. Statins are generally 
accepted as safe and well-tolerated, however very real risks, including myopathies and 
rhabdomyolysis, have been well documented (74, 118). Additionally, recent reports have suggested 
that statins may carry a risk of kidney injury.    
The relationship between statin use and kidney function is not well understood. It has been 
suggested that statin use may be beneficial towards overall kidney function (54), yet the 
cardiovascular protective effects of statins have not been demonstrated in dialysis and renal transplant 
patients as in the general population (55). It has been suggested by one observational study that the 
risk of AKI may be increased in both male and female statin users (33), and meta-analyzed clinical 
trial data showed an increased risk of proteinuria in individuals taking higher-dosages of rosuvastatin 
(58). However, in 2006 the Kidney Expert Panel of the National Lipid Association’s Safety Task 
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Force issued a statement that there was not evidence suggesting a link between statin exposure and 
renal injury (56, 57). These reports justify increased research into the potential for statin-induced 
kidney injury. 
Non-experimental research of statin safety is difficult owing to statins’ widespread use and 
lack of a similar, exchangeable lipid treatment with which statins have clinical equipoise. Clinical 
trials or well-designed observational studies would employ a comparison group of non-users or other 
medication users who have a similar risk factor profile for the outcome. However, an exchangeable 
comparison group is difficult to identify in non-observational settings (70), particularly in 
administrative claims, where difficult-to-measure factors such as healthy lifestyle and behaviors, 
access to and utilization of healthcare, and clinical factors which would not be reflected in billing 
claims (obesity, smoking, family history, etc.) can all contribute to both the risk of AKI and a patient 
initiating a statin.  
In this administrative claims-based study employing a very large cohort from the United 
States, we used modern epidemiologic methods and careful patient inclusion criteria to evaluate the 
association between statin initiation and AKI. We also evaluated and the comparative safety of 
individual statin formulations and higher- versus lower-potency statins.  
2. Methods 
Study population 
We employed two large employer-based insurance claims databases: the Thomson Reuters’ 
MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of 
Benefits Databases (Thomson Reuters (Healthcare) Inc., 2011). These databases are compilations of 
insurance billing data from approximately 100 large, employer-based insurance plans and Medicare 
supplementary plans from across the United States. Adjudicated, paid inpatient, outpatient, and 
pharmacy claims, as well as enrollment information, are available in the databases for employees, 
dependents and retirees. 
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Treatment ascertainment 
Statin initiators were identified from a pharmacy dispensing claim for any statin following 
180 days free of a statin use. We required at least one, non-statin medication claim during the 180-day 
baseline period to ensure pharmacy benefit status and system utilization. The formulation of the index 
statin prescription was noted, and the prescription was labeled as either higher- or lower-potency 
based on formulation and dosage. The date of the initial statin prescription was considered the index 
date, and from that point forward the patient was considered a statin initiator in an intent-to-treat 
analysis.  
Initiators of cerivastatin sodium were excluded due to its documented increased risk of 
myopathy and rhabdomyolysis and subsequent removal from the market (59, 119). 
A cohort of non-statin users was obtained by identifying individuals with an outpatient 
physician’s visit following 180 statin-free days. Similarly to the statin users, non-users were required 
to have at least one other medication dispensing during baseline.  
Outcome 
In- and outpatient claims in the one year following the index date were searched for 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis 
codes for evidence of acute renal failure (ARF) (ICD-9-CM 584.5 – 584.9). The validity of these 
codes has been investigated (79, 113), and while the sensitivity has been shown to be quite low, the 
specificity is very high. However, valid research can still be performed in situations with very high 
specificity under the assumption of no differential misclassification across treatment groups (114, 
115).    
An expanded renal failure definition was also considered, which included ARF, end-stage 
renal disease (ICD-9-CM 585.6), unspecified renal failure (ICD-9-CD 586), or a procedure code for 
dialysis (see Appendix 1). 
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Comparisons 
 Statin initiators were compared to the identified non-users, and the analysis was stratified by 
multiple clinically-relevant subgroups at higher-risk for AKI, including individuals aged 65 years and 
older, and those with diabetes, hypertension, recent acute coronary syndrome, or chronic kidney 
disease (CKD). We also compared initiators of higher-potency statins to lower-potency formulations 
and dosages. Lastly, we compared initiators of individual statin formulations to higher-potency 
atorvastatin users. In instances where formulations could exist in both higher- and lower-potency 
forms (e.g. atorvastatin, lovastatin, rosuvastatin, and simvastatin), the potencies were considered 
separately (see Table 6.1). 
Covariate information 
In- and outpatient claims in the 180 days prior to and including the index date were 
investigated for diagnosis and procedure codes for cardiovascular disease risk factors and indicators, 
recent acute events, healthcare utilization, and risk factors for AKI.  
Pharmacy dispensing claims during the baseline window were searched for prevalent use of 
additional medications. Medications newly-initiated following six months free of the medication on 
the same day as or within one day of the statin initiation were considered concurrently initiated, and 
were considered as separate variables in the analysis. 
Statistical analyses 
Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% 
confidence intervals (CI) for the one-year risk of statin initiation on AKI. Follow-up began the day 
after statin initiation, and continued until censoring at the event of interest, plan unenrollment, one 
year after statin initiation, or end of the study period (December 31, 2010).   
All analyses were performed using SAS 9.2 (SAS Institute, Inc., Cary, NC). 
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Propensity score calculation and application 
We estimated the predicted probability of statin initiation, or propensity score (PS), using the 
measured covariates in logistic regression models for each comparison in this analyses. Each 
distribution of the PS by treatment group was plotted to assess the exchangeability of the treatment 
groups with respect to the measured confounders. 
Propensity score matching. Within each analysis, we matched individuals in the treatment 
group to individuals in the comparison group using a 5-1 greedy matching algorithm (109). The HR 
was estimated within the matched cohort. This method estimates the effect of the treatment only in 
those who received treatment rather than the entire population. In this method, individuals without a 
match are excluded from the analysis. 
Standardized morbidity ratio weighting. The PS was also used to calculate standardized 
morbidity ratio weights (SMRW), in which treated individuals were unweighted, and untreated 
patients received a weight of [PS / (1 – PS)] . This techniques retains all individuals in the analysis, 
but it downweights untreated individuals with very low predicted probability of treatment, and 
upweights those untreated individuals with higher probability.  These weights were applied to Cox 
proportional hazards models estimating the treatment effect in the treated. 
To reduce the influence of extreme weights caused by those treated contrary to prediction 
(108) and to ensure positivity by restricting to portions of the PS distribution with comparable treated 
and untreated individuals (120), analyses were repeated with PS non-overlap extreme weights 
trimmed. All individuals with PS less than the 0.5th percentile of the treated or the 99.5thpercentile of 
the untreated were excluded. In a series of sensitivity analyses, these cutoffs were progressively 
moved inward toward the median by 0.5 percentiles. 
Propensity score stratification. In comparison groups with considerable non-overlap of PS 
distributions between the treated and non-treated, we stratified the cohort into 50 equal groups by the 
distribution of the propensity score. Covariates between treated and untreated individuals should be 
balanced within each strata (121). We estimated crude HR among each stratum and plotted them to 
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observe any modification of the effect measure estimate across the distribution of the propensity 
score. 
Ethical approval 
This analysis using deidentified billing claims was ruled exempt from further review by the 
Institutional Review Board of the University of North Carolina at Chapel Hill (UNC). 
Role of the funding source 
This study was funded through a training grant in renal epidemiology from the National 
Institutes of Health to the UNC Kidney Center (grant number 5 T32 DK007750-13). The funding 
source played no role in the design, analysis, or interpretation of this study. 
3. Results 
Statin users vs. non-users 
We identified 4,146,506 statin initiators and 4,033,800 non-users eligible for the analysis. 
The distributions of covariates by treatment group are shown in Table 6.2. The statin users were 
substantially older, had more cardiovascular disease, more healthcare utilization, more comorbidities, 
and have more prevalent medication use and concurrent medication initiation. Analysis of the 
distribution of the propensity score by treatment group revealed considerable non-overlap between 
the statin users and non-users (see Figure 6.1), suggesting little comparability between the treatment 
groups. 
AKI was observed during one-year of follow-up in 0.9% of the statin users and 0.3% of the 
non-users. Cox-proportional hazards models revealed a crude HR of 3.11 (95% CI: 3.04, 3.17). Upon 
multivariable adjustment, the effect estimate was attenuated to HR=0.97 (0.94, 0.99) (see Table 6.3). 
Upon propensity score matching of the statin initiators to non-users, 1,522,017 matched pairs 
remained for analysis, resulting in HR=0.79 (95% CI: 0.76, 0.81). The vast majority of participants 
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were excluded from the resulting analysis due to failure to match in the non-overlapping regions of 
the propensity score (see Figure 6.1).  
Upon SMRW weighting and trimming the most extreme 0.5th and 99.5th percentiles of the 
treated and untreated PS distributions, respectively, the estimate was HR=0.76 (95% CI: 0.76, 0.79). 
When the expanded, any kidney failure outcome definition was considered, the effect 
measure estimates remained almost identical for all comparisons. 
The cohort was divided into 50 strata of the propensity score, and the HR was calculated 
within each stratum. The results were plotted (see Figure 6.2), and the HR remained constant at a 
mild protective effect across the majority of the strata, with exceptions of the tails of the PS 
distribution. The risk of AKI seemed to be highly elevated among statin users at the lower fifth of the 
PS. We compared the covariate distributions by treatment status among select strata at the lower tail 
of the PS distribution to investigate potential causes of the treatment effect heterogeneity. The 
patients in both treatment groups in this lower tail were younger and had fewer CVD risk factors or 
procedures than the general sample. 
We investigated the treatment effect of statin use within clinically relevant subgroups. The 
rates of AKI were highest in those with CKD and the elderly, as expected. The relative effect of statin 
initiation appeared constant over all subgroups within each estimation technique (see Table 6.4). 
Higher-potency vs. lower-potency statin users 
Of the statin users, 3,055,038 initiated a higher-potency statin and 1,085,202 initiated a 
lower-potency statin. The distribution of covariates between statin treatment groups was very similar, 
as evidenced by the more extensive PS overlap among the treatment groups (see Figure 6.3). All 
effect measure estimation techniques yielded very similar, null-to-minimal effects of higher-potency 
statin initiation versus lower-potency statins on AKI (see Table 6.5). 
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Comparative safety of statin formulations 
The risks of AKI in individual statin formulations were compared to higher-potency 
atorvastatin. PS matching and multivariable adjusted estimates revealed very similar hazards of AKI 
among the various formulations groups, just slightly below the AKI rate observed in higher-potency 
atorvastatin. A notable exception was seen in higher-potency simvastatin, which showed a slightly 
increased risk of AKI compared to higher-potency atorvastatin: multivariable HR = 1.18 (95% CI 
1.05, 1.11); PS-matched HR = 1.16 (95% CI: 1.00, 1.08) (see Figure 6.4).  
4. Discussion 
Initiation of statins was not shown to be associated with an increase in AKI in the majority of 
statin initiators, nor were higher-potency statins shown to be convey higher AKI risk than lower-
potency statins. These findings were robust across renal failure definitions. PS-based methods may 
suggest a very modest protective effect of statin use against one-year risk of AKI, but the effect was 
very mild. The stratified analysis revealed that for many statin initiators, there appeared to be a 
protective effect against AKI, yet in those treated contrary to prediction in the tails of the propensity 
score distribution (108) appear to be a different effect.  
There were some differences observed between the effect measure estimates yielded by the 
multivariable outcome model that showed a null effect, and the PS models that suggest a mild 
protective effect may be present. The multivariable adjustment considers all strata equally, while the 
PS matched and SMRW weighted models exclude or down-weight the individuals with extreme PS, 
focusing only on the treated individuals and comparable untreated individuals. The differences, 
therefore, between the null effect measure estimated by the outcome model and the protective 
estimates yielded by the PS-methods may be explained by the de-emphasis or exclusion of the 
untreated individuals in the lower strata of the PS distributions, or the trimming of the heavily-
weighted untreated individuals at the highest strata of the PS in the SMRW analysis (122). These 
results suggest that for the majority of statin initiators, statin use conveys no increased risk of AKI. 
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However, residual unmeasured confounding by frailty, severe disease state, or other factors in the 
tails of the PS distribution reduce our ability to draw inference about the effect of statins in these 
extreme strata.  
While the effect measure estimates resulting from the PS-based methods suggest a mild 
protective effect, this must be interpreted conservatively. The baseline rate of AKI in statin initiators 
was quite low (less that 1%), so the estimated absolute reduction of AKI in statin users is quite low. 
Additionally, the potential for unmeasured confounding and residual bias is still present, which could 
potentially influence the results.  
This work must be interpreted in light of several important limitations. As with all 
administrative claims-based studies, information on kidney function, cardiovascular risk, and other 
covariates and outcomes is derived from submitted claims for reimbursement, rather than 
biomeasurements or medical records. Consequently, information on key risk factors for AKI and 
CVD such as glomerular filtration rate, blood lipids, obesity, smoking, and family history of CVD or 
renal disease may be unavailable for inclusion in analysis, leaving the possibility for residual 
confounding. In particular, baseline kidney function, one of the stronger predictors of AKI, can only 
be ascertained through the use of billing codes for chronic kidney disease, which have been shown to 
be very insensitive measures (113). 
Additionally, due to the incomparability between the statin and non-user treatment groups, 
the PS-based estimates are not applicable to the entire statin initiating population. Exclusion of non-
matching individuals and trimming of extreme weights limit the population to whom the estimates 
can be generalized. The stratified analysis suggests that for the majority of initiators, the reported 
effect measure estimates are valid. However, these effects were not observed in statin users with low 
predicted probability of statin treatment by our estimation. Investigation of the covariate distribution 
among the lower tail revealed that those in the lowest strata of the PS were very young adults with 
minimal-to-no prior cardiovascular procedures or diagnoses. The statin users appear to be initiating 
the medication for some unknown and unmeasured purpose, while they are being compared to 
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perfectly healthy young adults. We would expect these comparisons, atypical of the general statin-
initiating population, to yield estimates showing statin users at higher risk of adverse events, but this 
effect is likely due to unmeasured confounding than an actual drug effect. When the analysis was 
restricted to individuals aged 65+, the heterogeneity in the lower tail of the PS disappeared, resulting 
in much more homogeneous treatment effect (see Figure 6.5). 
There appeared to be very little difference in risk of AKI among users of higher- versus 
lower-potency or individual statin formulations, with the exception of higher-potency simvastatin, 
which demonstrated a larger AKI risk than higher-potency atorvastatin and other formulations. This 
finding is consistent with the prevailing safety information of high-dosage simvastatin, which has 
similarly demonstrated a higher risk of myalgia within the first year of therapy (123), prompting the 
Food and Drug Administration to limit the use of 80 mg (the highest available dose) to only those 
with at least 12 months free of adverse events (124). 
Among the vast majority of typical statin users, we found no increased risk of AKI due to the 
medication initiation across subgroups and statin formulations. Non-randomized studies of statin 
effects must take great care in their choice of comparison groups and analysis techniques to estimate 
effect measures among exchangeable comparison groups to produce unbiased estimates of statin 
safety. 
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5. Tables 
Table 6.1 Statin potencies by formulation and dosage 
Formulation Higher-potency dosages Lower-potency dosages 
Atorvastatin > 10 mg ≤ 10 mg 
Fluvastatin none all 
Lovastatin > 40 mg ≤ 40 mg 
Pravastatin none all 
Rosuvastatin > 5mg ≤ 5 mg 
Simvastatin > 40 mg ≤ 40 mg 
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Table 6.2 Distribution of patient characteristics by treatment group 
 Statin non-initiator 
 (n=4,033,800) 
Statin initiator 
 (n=4,146,506) 
 
DEMOGRAPHICS 
 
N 
 
% 
 
N 
 
% 
Male, % 1,494,210 37.0 1,984,993 47.9 
Mean age, standard deviation (SD) 45.6 16.2 58.5 12.6 
MarketScan Database      
 Commercial Claims and Encounters 
Database, % 
3,536,515 87.7 2,952,772 71.2 
 Medicare Supplementary Database, % 497,285 12.3 1,193,734 28.8 
 
CARDIOVASCULAR DISEASE 
MANAGEMENT 
 
N 
 
% 
 
N 
 
% 
Angiography performed, % 1,821 0.1 36,368 0.9 
Cardiac stress test performed, % 39,218 1.0 385,572 9.3 
Echocardiograph, % 72,859 1.8 488,892 11.8 
Mean number of lipid tests, SD 0.18 0.48 0.83 1.00 
Mean number of creatinine measurements, SD 0.00 0.07 0.01 0.16 
 
CVD & COMORBID CONDITIONS 
 
N 
 
% 
 
N 
 
% 
Diabetes 155,745 3.9 949,562 22.9 
Chronic kidney disease  9,073 0.2 67,680 1.6 
Other kidney disease 2,065 0.1 11,488 0.3 
Proteinuria 727 0.0 2,401 0.1 
Hypertension 485,017 12.0 1,595,038 38.5 
Hyperlipidemia 245,087 6.1 1,926,172 46.5 
Ischemic heart disease* 46,558 1.2 549,580 13.3 
Atrial fibrillation 25,537 0.6 131,964 3.2 
Chronic liver disease or cirrhosis 17,557 0.4 52,300 1.3 
Multiple myeloma 723 0.0 2,759 0.1 
Systemic lupus erythematosus 4,691 0.1 16,486 0.4 
Metabolic disorders 12,257 0.3 43,320 0.8 
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ACUTE EVENTS N % N % 
Myocardial infarction (MI) in previous 2 weeks 3,092 0.1 70,402 1.7 
MI, within previous 6 months 5,607 0.1 93,491 2.3 
History of MI  2,074 0.1 25,081 0.6 
Unstable angina in previous 2 weeks 3,865 0.1 67,141 1.6 
Unstable angina in previous 6 months 3,511 0.1 37,720 0.9 
Stroke 33,198 0.8 223,446 5.4 
Coronary artery bypass graft 1,259 0.0 34,345 0.8 
Insertion of a coronary stent 2,270 0.1 95,306 2.3 
Angioplasty 569 0.0 12,963 0.3 
Heart failure 23,854 0.6 119,730 2.9 
Spesis 1,258 0.0 3,289 0.1 
 
PREVALENT MEDICATION USE DURING 
BASELINE 
 
N 
 
% 
 
N 
 
% 
Angiotensin converting enzyme (ACE) inhibitors 367,355 9.1 1,093,563 26.4 
Angiotensin receptor blockers (ARBs) 172,440 4.3 580,626 14.0 
Beta blockers 352,496 8.7 1,018,742 24.6 
Calcium channel blockers 257,730 6.4 706,410 17.0 
Anti-platelet agents 41,140 1.0 231,225 5.6 
Alpha blockers 58,389 1.5 186,631 4.5 
Thiazide diuretics 400,318 9.9 1,026,844 24.8 
Potassium-sparing diuretics 115,444 2.9 251,658 6.1 
Loop diuretics 76,685 1.9 269,089 6.5 
Niacin 9,745 0.2 62,518 1.5 
Fibrates 46,217 1.2 201,658 4.9 
Ezetimibe 16,641 0.4 118,049 2.9 
Anti-coagulants 45,911 1.1 163,722 4.0 
Non-steroidal anti-inflammatory agents (NSAIDs) 516,055 12.8 796,948 19.2 
MEDICATIONS INITIATED DURING 
EXPOSURE WINDOW 
 
N 
 
% 
 
N 
 
% 
ACE inhibitors 57,242 1.4 420,224 10.1 
ARBs 18,743 0.5 180,653 4.4 
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Beta blockers 42,248 1.1 362,681 8.8 
Calcium channel blockers 30,485 0.8 235,993 5.7 
Anti-platelet agents 3,923 0.1 155,649 3.8 
Alpha blockers 5,414 0.1 66,791 1.6 
Thiazides 61,429 1.5 285,918 6.9 
Potassium-sparing diuretics 14,904 0.4 60,332 1.5 
Loop diuretics 7,638 0.2 75,779 1.8 
Niacin 1,167 0.0 63,935 1.5 
Fibrates 4,849 0.1 56,057 1.4 
Ezetimibe 1,254 0.0 287,125 6.9 
Anti-coagulants 3,574 0.1 42,556 1.0 
NSAIDs 131,074 3.3 118,425 2.9 
 
  
 
Table 6.3 Effect measure estimates of statin initiation versus non-users on acute kidney injury 
   Acute kidney injury Any renal failure 
Analysis Treatment  
group 
N Events (%) HR* 95% CI* Events (%) HR 95% CI 
 Non-users 4,033,800 11,370 (0.3) -- -- 15,358 (0.4) -- -- 
Crude Statin users 4,146,506 37,542 (0.9) 3.11 3.04, 3.17 50,193 (1.2) 3.08 3.03, 3.14 
Multivariable adjusted    0.97 0.94, 0.99  1.03 1.01, 1.05 
         
Trimmed SMRW* Non-users 2,953,843 10,726 (0.4) -- -- 14,423 (0.5) -- -- 
 Statin users 3,466,441 23,569 (0.7) 0.76 0.73, 0.79 31,823 (0.9) 0.76 0.73, 0.78 
         
Propensity score matching Non-users 1,552,017 8,836 (0.6) -- -- 11,976 (0.8) -- -- 
 Statin users 1,552,017  7,170 (0.5) 0.79 0.76, 0.81 9,928 (0.6) 0.80 0.78, 0.83 
*HR, Hazard ratio; CI, Confidence interval; SMRW, standardized mortality ratio weighting 
 
71 
 
  
 
Table 6.4 Effect of statin initiation versus non-use in relevant subgroups 
   Crude Adjusted Matched SMRW 
Subgroup N Events %  HR* 95%CI* HR 95%CI HR 95%CI HR 95%CI 
Aged 65+ 1,659,385 6.5 1.43 1.42, 1.45 0.97 0.95, 0.98 0.83 0.81, 0.84 0.82 0.80, 0.84 
CKD* 76,753 16.9 1.32 1.25, 1.40 0.96 0.90, 1.01 0.93 0.86, 1.00 0.69 0.47, 1.00 
Diabetes 1,105,308 4.6 1.23 1.20, 1.27 0.93 0.90, 0.95 0.78 0.75, 0.80 0.84 0.78, 0.91 
Hypertension 2,080,055 3.1 1.56 1.53, 1.60 1.00 0.98, 1.03 0.90 0.87, 0.92 0.87 0.82, 0.92 
Hyperlipidemia 2,171,259 1.5 1.96 1.87, 2.04 1.10 1.05, 1.15 0.98 0.93, 1.04 0.81 0.72, 0.92 
Recent ACS* 178,521 6.0 1.02 0.95, 1.09 0.92 0.86, 1.00 0.72 0.65, 0.80 0.71 0.49, 1.01 
*HR: Hazard ratio; CI: Confidence interval; CKD: Chronic kidney disease; ACS: Acute coronary syndrome 
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Table 6.5 Effect measure estimates of higher-potency versus lower-potency statin initiation on acute kidney injury 
   Acute kidney injury Any renal failure 
Analysis Treatment group N Events (%) HR* 95% CI* Events (%) HR 95% CI 
 Low potency 3,055,028 26,368 (0.9) -- -- 35,235 (1.2) -- -- 
Crude High potency 1,085,202 11,091 (1.0) 1.18 1.15, 1.20 14,849 (1.4) 1.18 1.16, 1.20 
Multivariable adjusted    1.09 1.07, 1.12  1.10 1.08, 1.12 
         
Trimmed SMRW* Low potency 3,002,718 10.693 (1.0) -- -- 34,211 (1.1) -- -- 
 High potency 1,066,544 25,638 (0.9) 1.08 1.05, 1.10 14,294 (1.3) 1.06 1.04, 1.08 
         
Propensity score matching Low potency 1,083,310 10,931 (1.0) -- -- 14,652 (1.4) -- -- 
 High potency 1,083,310 11,043 (1.0) 1.01 0.99, 1.04 12,790 (1.4) 1.01 0.99, 1.04 
*HR, Hazard ratio; CI, Confidence interval; SMRW, standardized mortality ratio weighting 
73 
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6. Figures 
 
 
Figure 6.1 Distribution of the propensity score between statin initiators and non-user 
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Figure 6.2 Effect of statin initiation on acute kidney injury across strata of the propensity score 
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Figure 6.3 Distribution of the propensity score (PS) between higher- and lower-potency statin initiators 
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Figure 6.4 Hazard ratios and 95% confidence intervals of the risk of acute kidney injury in statin formulations 
versus higher-potency atorvastatin  
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Figure 6.5 Hazard ratios and 95% confidence intervals of AKI among statin initiators vs. non-users across strata of 
the propensity score, ages 65+ 
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Chapter 7. Conclusions and public health significance 
Statins are widely used by a vast spectrum of Americans for primary and secondary 
prevention of CVD. With widespread use, particularly in relatively healthy populations, statins’ safety 
has become a pressing concern. Numerous observational studies of statins have been conducted, and 
recent concerns have been raised regarding the renal safety of statin use. To investigate these effects, 
we performed a study of statin initiators in a large, administrative claims database of privately-insured 
employed individuals and Medicare retirees. We investigated what additional information about statin 
initiators could be ascertained from pharmacy claims for other medications at the same time as the 
statin initiation. We also investigated the exchangeability of various comparison groups with statin 
initiators. 
We observed that statins were frequently initiated with other cardiovascular and non-
cardiovascular medications, presumably in response to a physician’s estimate of the patient’s CVD 
risk. In many cases, the exact characteristics making up one’s CVD risk may not be explicitly hard-
coded in administrative claims (e.g. family history of CVD, smoking status, obesity, lack of exercise, 
etc.), so concurrently initiated medications may be an important proxy for unmeasured and important 
confounding factors. Notably, rates of concurrent initiation were higher in groups with known higher 
CVD and renal risk, including those with recent acute events such as myocardial infarction or 
unstable angina, suggesting that consideration of concurrent initiation may be a useful factor in 
evaluating disease risk in other patient populations with less explicit risk factors.  
Medications may also be concurrently initiated as a result of better medical care. Particularly 
in the case of pre-CABG statin initiation, the statin may serve as a proxy for better pre-surgical 
evaluation and treatment. However, considering other medications initiated immediately prior to 
CABG allows us to control in some part for the unmeasured factors leading to statin initiation, which 
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may also influence the occurrence of post-CABG AKI. When considering these factors as well as 
other markers of CVD management, renal risk, healthcare utilization, and recent cardiovascular 
events, we found a mild protective effect of statin initiation on post-CABG AKI. After adjustment, 
we observed a protective effect of statin initiation on AKI (RR = 0.80, 95% CI 0.67, 0.96). This was 
robust throughout AKI definitions, varying exposure windows prior to CABG, and through most 
subgroups. However, this effect differed by age: ≥65 years, RR=0.90 (95% CI: 0.71, 1.14); <65 years, 
RR=0.69 (95% CI: 0.52, 0.91), although AKI was much more common in the older age group (8.1 vs. 
3.9%). Statin initiation immediately prior to CABG may modestly reduce the risk of post-operative 
AKI, yet the result is small and more pronounced in younger patients with a very low baseline risk of 
AKI. 
Lastly, we investigated the risk of AKI in a general statin-initiating population. Knowing a 
direct user vs. non-user design would be difficult due to the lack of an appropriate active drug 
comparison (e.g. another medication with a similar indication), and well described biases of statin use 
in primary prevention (e.g. the healthy user effect, where long-term preventive medication users are a 
highly-selected, healthier subgroup of medication users as compared to non-users) and secondary 
prevention (e.g. confounding by indication, where individuals who receive treatment are sicker and 
thus at higher risk of adverse events than non-users) settings, we employed multiple difference 
comparisons to comprehensively evaluate statins’ role in AKI. We compared statin users to non-
users, higher-intensity statins to lower-intensity statins, and individual statin formulations to 
atorvastatin. We also investigated the effect within more homogenous subgroups. We employed an 
array of propensity score techniques to evaluate the exchangeability of statin users with non-users, 
and found vast areas of minimal overlap between treated and untreated groups, making direct 
comparisons difficult. Propensity score matching, weighting, and stratification was employed, and all 
suggest no increase risk of AKI due to statin use in any individual formulation, potency, or subgroup, 
with the exception of higher-potency simvastatin, which has also been implicated for increased risk of 
muscle injury. 
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Heterogeneous treatment effects across the propensity score merit further exploration, as 
statin users come from a wide array of disease risk groups, and the reason for statin initiation is not 
always evident in claims data. Restriction to disease risk groups (e.g. older age, hypertension, recent 
acute events, etc.) removed much of this heterogeneity, but in younger, relatively healthier statin 
users, there appears to be an increased risk on AKI not seen in the vast majority of typical statin users. 
This is likely due to unmeasured confounding, and should not be generalized to the entire statin-
initiating population. 
Overall, statins do not appear to increase the risk of AKI in most cases, and may in fact, 
slightly reduce the incidence of AKI in pre-surgical settings. Lingering methodological concerns of 
non-randomized studies of statin use require that careful attention be paid to study design and analysis 
methods to estimate valid measures of statin safety and effectiveness. 
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Appendix 1 
Procedure codes for dialysis: 
V451, V56, V560, V560, V568, E8791, E8702, E8712, E8722, E8742, V5632, 0505F, 0507F, 3995, 
4052F, 4053F, 4054F, 4055F, 5498, 50360, 50365, 5569, 90935, 90937, 90940, 90945, 90947, 
90951, 90952, 90953, 90954, 90955, 90956, 90957, 90958, 90959, 90960, 90961, 90962, 90963, 
90964, 90965, 90966, 90967, 90968, 90969, 90970, 90999, 99512 
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